MeiraGTx Holdings (FRA:328) 3-Month Share Buyback Ratio: -15.64% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:328 MeiraGTx Holdings PLC FRA:328
60 GF Score
Price €12.10
GF Value €82.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is MeiraGTx Holdings 3-Month Share Buyback Ratio?

MeiraGTx Holdings FRA:328 -1.63% 60 3-Month Share Buyback Ratio is -15.64 as of Jun. 2026. GuruFocus rates FRA:328 with a GF Score™ of 60/100 and a GF Value™ of €82.13 (Possible Value Trap). The stock has 6 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. MeiraGTx Holdings's current 3-Month Share Buyback Ratio was -15.64%.


MeiraGTx Holdings  (FRA:328) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


MeiraGTx Holdings 3-Month Share Buyback Ratio Related Terms


FRA:328 vs CRVS, WVE, FBRX: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, MeiraGTx Holdings's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeiraGTx Holdings 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's 3-Month Share Buyback Ratio falls into.


FRA:328
60GF Score
MeiraGTx Holdings PLC FRA:328
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeiraGTx Holdings 3-Month Share Buyback Ratio Calculation

MeiraGTx Holdings's 3-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2026 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Mar. 2026 )
=(81.446 - 94.188) / 81.446
=-15.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -15.64 mean?
MeiraGTx Holdings (FRA:328) has a 3-Month Share Buyback Ratio of -15.64 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for MeiraGTx Holdings and its competitors.
Is MeiraGTx Holdings' 3-Month Share Buyback Ratio too high?
MeiraGTx Holdings' current 3-Month Share Buyback Ratio is -15.64. Overall, MeiraGTx Holdings has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' 3-Month Share Buyback Ratio compare to CRVS and WVE?
MeiraGTx Holdings' 3-Month Share Buyback Ratio of -15.64 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current 3-Month Share Buyback Ratio is -15.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €82.13, compared to a current price of €12.10 — trading 85.3% below its estimated fair value. The current 3-Month Share Buyback Ratio is -15.64. MeiraGTx Holdings' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current 3-Month Share Buyback Ratio is -15.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €12.10 is trading 85.3% below its estimated GF Value™ of €82.13. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for FRA:328:

  • 3-Month Share Buyback Ratio: -15.64
  • GF Value™: €82.13 vs. price of €12.10 (85.3% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA328:Germany
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
60GF Score

Get the complete analysis for FRA:328

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.10
Price
€82.13
GF Value